Cincinnati Eye Institute

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Macular degeneration3 trials
• Diabetic eye disease1 trial

Phase

• Phase 1/21 trial
• Phase 21 trial
• Phase 31 trial
• Phase 41 trial

Status

• Completed2 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Genentech, Inc.3 trials
• Hoffmann-La Roche1 trial

Running trials

• Recruiting

  A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

  NCT05626114· Phase 2· Genentech, Inc.· Source

• Active, not recruiting

  A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Phase 4· Genentech, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source